Filing Flows › Health Care › Polomar Health Services (PMHS)
Polomar Health Services (PMHS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Polomar Health Services (PMHS) Q2 2026 earnings results →
Q2 2026 Revenue up 27847% year over year to $1.5M · 13¢ of every $1 of revenue kept as net profit · operating margin 14.3%
Polomar Health Services made $1.5M in Q2 2026 (279× Y/Y). Operating margin 14.3%, net earnings $200K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.5M in Q2 2026, up 27847% year over year and up 52% from the previous quarter.
Gross margin was 61.2%, down 8.8 points from Q2 2025. Operating profit was $218K, a 14.3% margin (up 10312.9 points year over year). Operating expenses grew 27% against revenue growth of 27847%. The fastest-growing cost line was Sales & marketing (+4244%). Net earnings were $200K. The effective tax rate was 0.0%.
Operating cash flow was $121K, 61% of net earnings. Non-cash charges added back $9K of depreciation and amortization. Working capital and other items used $89K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $1.5M | 279× | 14.3% | $200K | $121K |
| Q1 2026 | 10-Q | Jun 1, 2026 | $1.0M | 221× | -0.7% | −$25K | $34K |
| Q4 2025 | 10-K | May 6, 2026 | $632K | 30× | n/m | −$9.0M | $190K |
| Q3 2025 | 10-Q | Nov 25, 2025 | $6K | -37% | n/m | −$650K | −$353K |
| Q2 2025 | 10-Q | Aug 19, 2025 | $5K | -62% | n/m | −$606K | −$188K |
| Q1 2025 | 10-Q | Jun 30, 2025 | $5K | -67% | n/m | −$457K | −$46K |
| Q4 2024 | 10-K | May 22, 2025 | $21K | +21% | n/m | −$719K | −$315K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Polomar Health Services
Polomar Health Services, Inc. (the “Company”), operates Polomar Specialty Pharmacy, LLC, a State of Florida licensed retail compounding pharmacy, located in Palm Harbor, FL, pursuant to license # PH35196 (“Polomar Pharmacy”). Polomar Pharmacy is also licensed as a Special Sterile Compounding Pharmacy, permit #PH35277, which authorizes the licensed entity to dispense injectable and other sterile compounds (eye drops, infused therapeutics) upon receipt of a valid prescription. The compounding facility operates pursuant to guidelines established under Sec. 503A “Compounding Pharmacy” of the Federal Food, Drug and Cosmetic Act. Section 503A authorizes the licensed entity to manufacture compounded drugs and fulfill prescriptions provided to it by state licensed physicians and other licensed healthcare professionals including physician assistants and nurse practitioners.
In its own words, from its 10-Q, filed Aug 14, 2026.
Polomar Health Services against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 279× against the peers' median +10%. Operating margin: 14.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PMHS Polomar Health Services | Q2 2026 | $1.5M | 279× | 14.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Polomar Health Services 10-Q on SEC EDGAR · CIK 1265521 · Pharmaceutical Preparations
More on PMHS
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results